AIMS/HYPOTHESIS: Prevention trials in first-degree relatives of type 1 diabetic patients are hampered by large interindividual differences in progression rate to diabetes. We investigated whether specific combinations of immune and genetic markers can identify subgroups with more homogeneous progression to clinical onset. METHODS: Antibodies against islet cell cytoplasm (ICA), insulin (IAA), glutamate decarboxylase (GADA) and IA-2 protein (IA-2A) were measured in 790 non-diabetic control subjects and 4,589 first-degree relatives under age 40. RESULTS: On first sampling, 11.1% of the siblings presented at least one antibody type (p<0.001 vs other relatives). During follow-up (median 52 months) 43 subjects developed type 1 diabetes (31 siblings, ten offspring of a diabetic father, two offspring of a diabetic mother). Using Kaplan-Meier survival analysis and Cox regression, IA-2A conferred the highest 5-year diabetes risk (>50%) irrespective of the number of antibodies present. In initially IA-2A-positive relatives (n=58) progression to hyperglycaemia depended more on HLA DQ status than on type of kinship (84% progression in the presence of DQ2/DQ8 vs 32% in its absence; p<0.003). In IA-2A-negative relatives (n=4,531) 5-year progression to diabetes increased with the number of other antibodies (ICA, GADA and/or IAA) (p<0.001) but overall did not exceed 10% even for two or more antibodies. Among relatives initially positive for one or more antibody type other than IA-2A (n=315), there was significantly more progression to diabetes (overall still <10%) in carriers of DQ2 (p<0.001 vs no DQ2), regardless of DQ8 status. CONCLUSIONS/ INTERPRETATION: These observations suggest that the HLA-DQ-inferred risk of diabetes can proceed through two distinct pathways distinguished by IA-2A status. Combined positivity for DQ2/DQ8 and IA-2A defines a more homogeneous high-risk population for prevention trials than those used so far.
AIMS/HYPOTHESIS: Prevention trials in first-degree relatives of type 1 diabeticpatients are hampered by large interindividual differences in progression rate to diabetes. We investigated whether specific combinations of immune and genetic markers can identify subgroups with more homogeneous progression to clinical onset. METHODS: Antibodies against islet cell cytoplasm (ICA), insulin (IAA), glutamate decarboxylase (GADA) and IA-2 protein (IA-2A) were measured in 790 non-diabetic control subjects and 4,589 first-degree relatives under age 40. RESULTS: On first sampling, 11.1% of the siblings presented at least one antibody type (p<0.001 vs other relatives). During follow-up (median 52 months) 43 subjects developed type 1 diabetes (31 siblings, ten offspring of a diabetic father, two offspring of a diabetic mother). Using Kaplan-Meier survival analysis and Cox regression, IA-2A conferred the highest 5-year diabetes risk (>50%) irrespective of the number of antibodies present. In initially IA-2A-positive relatives (n=58) progression to hyperglycaemia depended more on HLA DQ status than on type of kinship (84% progression in the presence of DQ2/DQ8 vs 32% in its absence; p<0.003). In IA-2A-negative relatives (n=4,531) 5-year progression to diabetes increased with the number of other antibodies (ICA, GADA and/or IAA) (p<0.001) but overall did not exceed 10% even for two or more antibodies. Among relatives initially positive for one or more antibody type other than IA-2A (n=315), there was significantly more progression to diabetes (overall still <10%) in carriers of DQ2 (p<0.001 vs no DQ2), regardless of DQ8 status. CONCLUSIONS/ INTERPRETATION: These observations suggest that the HLA-DQ-inferred risk of diabetes can proceed through two distinct pathways distinguished by IA-2A status. Combined positivity for DQ2/DQ8 and IA-2A defines a more homogeneous high-risk population for prevention trials than those used so far.
Authors: M Landin-Olsson; H J Arnqvist; G Blohmé; B Littorin; F Lithner; L Nyström; B Scherstén; G Sundkvist; L Wibell; J Ostman; A Lernmark Journal: Autoimmunity Date: 1999 Impact factor: 2.815
Authors: F K Gorus; P Goubert; C Semakula; C L Vandewalle; J De Schepper; A Scheen; M R Christie; D G Pipeleers Journal: Diabetologia Date: 1997-01 Impact factor: 10.122
Authors: C F Verge; R Gianani; E Kawasaki; L Yu; M Pietropaolo; R A Jackson; H P Chase; G S Eisenbarth Journal: Diabetes Date: 1996-07 Impact factor: 9.461
Authors: F K Gorus; C L Vandewalle; H Dorchy; P Van Crombrugge; F C Schuit; D G Pipeleers Journal: J Clin Endocrinol Metab Date: 1994-05 Impact factor: 5.958
Authors: S Caillat-Zucman; H J Garchon; J Timsit; R Assan; C Boitard; I Djilali-Saiah; P Bougnères; J F Bach Journal: J Clin Invest Date: 1992-12 Impact factor: 14.808
Authors: S Genovese; R Bonfanti; E Bazzigaluppi; V Lampasona; E Benazzi; E Bosi; G Chiumello; E Bonifacio Journal: Diabetologia Date: 1996-10 Impact factor: 10.122
Authors: F Cucca; J V Goy; Y Kawaguchi; L Esposito; M E Merriman; A J Wilson; H J Cordell; S C Bain; J A Todd Journal: Nat Genet Date: 1998-07 Impact factor: 38.330
Authors: I Truyen; P De Pauw; P N Jørgensen; C Van Schravendijk; O Ubani; K Decochez; E Vandemeulebroucke; I Weets; R Mao; D G Pipeleers; F K Gorus Journal: Diabetologia Date: 2005-10-07 Impact factor: 10.122
Authors: J De Grijse; M Asanghanwa; B Nouthe; N Albrecher; P Goubert; I Vermeulen; S Van Der Meeren; K Decochez; I Weets; B Keymeulen; V Lampasona; J Wenzlau; J C Hutton; D Pipeleers; F K Gorus Journal: Diabetologia Date: 2009-11-29 Impact factor: 10.122
Authors: I Truyen; J De Grijse; C Van Schravendijk; D De Smet; K Decochez; E Vandemeulebroucke; M Giri; B Keymeulen; C Mathieu; L Van Gaal; P De Pauw; I Weets; D G Pipeleers; F K Gorus Journal: Diabetologia Date: 2007-08-09 Impact factor: 10.122
Authors: I Truyen; J De Grijse; I Weets; L Kaufman; L Pipeleers; N Nanos; K Decochez; R Hilbrands; J-M Kaufman; B Keymeulen; C Mathieu; L Van Gaal; D G Pipeleers; F K Gorus Journal: Clin Exp Immunol Date: 2007-05-22 Impact factor: 4.330
Authors: F K Gorus; E V Balti; I Vermeulen; S Demeester; A Van Dalem; O Costa; H Dorchy; S Tenoutasse; T Mouraux; C De Block; P Gillard; K Decochez; J M Wenzlau; J C Hutton; D G Pipeleers; I Weets Journal: Clin Exp Immunol Date: 2013-01 Impact factor: 4.330
Authors: Anette G Ziegler; Marian Rewers; Olli Simell; Tuula Simell; Johanna Lempainen; Andrea Steck; Christiane Winkler; Jorma Ilonen; Riitta Veijola; Mikael Knip; Ezio Bonifacio; George S Eisenbarth Journal: JAMA Date: 2013-06-19 Impact factor: 56.272
Authors: Eric Mbunwe; Bart J Van der Auwera; Ilse Vermeulen; Simke Demeester; Annelien Van Dalem; Eric V Balti; Sara Van Aken; Luc Derdelinckx; Harry Dorchy; Jean De Schepper; Chris van Schravendijk; Janet M Wenzlau; John C Hutton; Daniël Pipeleers; Ilse Weets; Frans K Gorus Journal: Diabetes Date: 2012-11-16 Impact factor: 9.461